Allogene Therapeutics (ALLO) Earns Buy Rating from Analysts at Goldman Sachs Group

Goldman Sachs Group started coverage on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research report sent to investors on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $41.00 price target on the stock.

Allogene Therapeutics stock opened at $28.35 on Monday. Allogene Therapeutics has a 1 year low of $21.67 and a 1 year high of $28.90.

In other Allogene Therapeutics news, Director Arie Belldegrun bought 35,000 shares of the business’s stock in a transaction on Monday, October 15th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $630,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider David D. Chang bought 40,000 shares of the business’s stock in a transaction on Monday, October 15th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $720,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 750,000 shares of company stock worth $13,500,000.

Read More: Retained Earnings

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply